PIII

Business Context and Reporting Period

P3 Health Partners Inc. (P3) is a patient-centered, physician-led population health management company operating primarily in the Medicare Advantage market. The company utilizes an at-risk shared savings model, contracting with health plans to manage the total healthcare needs of members in exchange for fixed monthly capitation payments. This Form 10-Q covers the quarterly period ended June 30, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total operating revenue increased 15% year-over-year for the quarter and 22% for the six-month period. This was primarily driven by a 23% increase in at-risk members (from 104,100 to 128,100) due to the addition of nine new counties under contract effective January 1, 2024.
• Medical Expenses: Medical expenses rose 21% for the quarter and 27% for the six-month period, consistent with the growth in membership. Medical expenses represented 96% of total revenue for the quarter.
• Operating Expenses: Corporate, general, and administrative expenses decreased 2% for the quarter and 17% for the six-month period, largely due to reduced professional fees related to public company operations.
• Warrant Liability: The company recorded a significant non-cash gain of $8.7 million for the quarter and $8.9 million for the six months due to the mark-to-market adjustment of stock warrants, which improved the net loss position.
• Debt Structure: In March 2024, the company entered into a new $25.0 million unsecured promissory note (VGS 2 Promissory Note) with an interest rate of 17.5% (payable in-kind or partially in cash).

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern within one year of the filing date. The company expects to continue incurring operating losses and negative cash flows from operations.
• Liquidity and Capital: As of June 30, 2024, the company held $78.2 million in cash and restricted cash. In May 2024, it completed a private placement raising approximately $39.8 million net of costs. The company continues to explore additional debt and equity financing.
• Nasdaq Compliance: The company received a deficiency letter from Nasdaq on May 15, 2024, regarding its stock price closing below the $1.00 minimum bid price requirement for 31 consecutive days. It has until November 11, 2024, to regain compliance.
• Internal Controls: The company identified material weaknesses in its internal control over financial reporting, including deficiencies in accounting policies, risk assessment, and IT general controls. These weaknesses remained unremediated as of June 30, 2024.
• Unusual Items: The financial results include a $3.4 million benefit from the premium deficiency reserve for the quarter, reflecting management's assessment that increased membership and contract maturation will reduce future losses.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $78.2 million cash balance against projected operating losses and debt service obligations given the "substantial doubt" going concern warning.
• Debt Covenants: Review the specific financial covenants (e.g., minimum liquidity, annual revenue targets) in the Term Loan Facility and VGS notes to assess default risk.
• Nasdaq Status: Monitor the stock price to determine if the company will meet the $1.00 bid price requirement by November 11, 2024, to avoid delisting.
• Medical Margin Trends: Analyze the medical margin per member to ensure that the rapid growth in membership (23% increase) is not diluting profitability faster than anticipated.
• Internal Control Remediation: Assess the progress of remediation efforts for the identified material weaknesses in financial reporting controls.